A Decision Support Tool for Pancreatic Cancer Screening -Aim 2

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-99
SponsorUNC Lineberger Comprehensive Cancer Center

About this trial

Pancreatic cancer has a rising incidence and poor survival. Early detection in high-risk individuals may substantially improve outcomes. Although guidelines recommend screening for individuals with hereditary cancer syndromes or certain genetic variants, pancreatic cancer screening remains uncertain due to limited evidence of mortality benefit, unclear screening strategies, potential harms, resource requirements, and low adherence. Shared decision-making between patients and providers is therefore essential, but no decision aid currently exists to support pancreatic cancer screening decisions. This record covers Aim 2, which will evaluate the acceptability, feasibility, and implementation of an electronic decision support tool designed to improve shared decision-making, value-concordant care, and screening adherence. The pilot study will also provide training in clinical trial methodology and support development toward an independent research career.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adults who are eligible for pancreatic cancer screening according to current National Comprehensive Cancer Network guidelines.

Not currently enrolled in a pancreatic cancer screening program.

Referred to or previously seen at the UNC High Risk GI Cancer Clinic.

English-speaking.

Disqualifiers

Currently enrolled in a pancreatic cancer screening program.

Does not meet pancreatic cancer screening eligibility criteria according to National Comprehensive Cancer Network guidelines.

Unable or unwilling to provide informed consent.

Non-English speaking.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Electronic Decision Support Tool

    Behavioral

    Participants will use an electronic decision support tool designed to facilitate shared decision-making about pancreatic cancer screening. The pilot study will evaluate the tool's acceptability, feasibility, and implementation in clinical practice.

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: Electronic Decision Support ToolExperimental treatment 1 intervention
Group B: Standard of CareNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Acceptability of the decision support tool

Participant-reported acceptability of the electronic decision support tool, assessed using a validated acceptability measures: acceptability of intervention measure (AIM) and intervention appropriateness measure (IAM). The minimum score for both measures is 4 (all items rated "1 - Completely Disagree") and the maximum score is 20 (all items rated "5 - Completely Agree").

Time frame
Up to 3 months
2

Feasibility, Barriers, and Facilitators of Implementing the Decision Support Tool - Recruitment Rate

Recruitment rate, defined as the proportion and number of eligible participants who enroll in the study, will be used to assess the feasibility of integrating and implementing the electronic decision support tool in clinical practice.

Time frame
Up to 3 months
3

Feasibility, barriers, and facilitators of implementing the decision support tool - retention rate

Retention rate, defined as the number and proportion of enrolled participants who complete use of the electronic decision support tool and all study-related assessments, will be used to assess the feasibility of integrating and implementing the tool in clinical practice.

Time frame
Up to 3 months

Secondary outcomes

1

Change in score on 5 question knowledge assessment

Difference between participants' post-visit and pre-visit knowledge scores regarding the screening decision. Change in knowledge will be defined as the difference between participants' post-visit and pre-visit knowledge scores on a five-item knowledge assessment, calculated as the post-knowledge score minus the pre-knowledge score. Pre- and post-knowledge scores will be calculated by summing correct answers (equal to 1) and incorrect or incomplete responses (equal to 0). The assessment will be administered immediately before and after the clinic visit.

Time frame
Up to 3 months
2

Rate of Decision-Concordant Care

If the participant undergoes the screening test documented during the clinic visit within 3 months of the visit, this will be considered decision-concordant care. The rate of decision concordant care will be equal to the number of participants who underwent decision-concordant care divided by the total number of participants in the study. Medical record/chart review will be used for measurements

Time frame
Up to 3 months
3

Duration of the clinic visit

Duration of the clinic visit will be measured as the duration of the index clinic visit using available clinical or electronic medical record timestamps. This measure will be used to evaluate whether the intervention affects the amount of time required to complete the clinic visit.

Time frame
Up to 3 months
4

Patient-reported assessment of shared decision-making quality -1

Patient-reported assessment of the quality of the shared decision-making process, including the extent to which patients received information about available options, understood the benefits and risks of those options, and had their preferences considered in the decision. It will be measured using the collaboRATE questionnaire, administered immediately following the clinic visit and using the 9-item Shared Decision-Making Questionnaire (SDM-Q-9). The SDM-Q-9 measures the extent to which patients perceive that key components of shared decision-making occurred during the clinical encounter. The minimum score for the SDM-Q-9 is 0 (all items rated "0 - Completely Disagree") and the maximum score is 45 (all items rated "5 - Completely Agree"). Higher scores indicate a patient perception of better shared decision making. It will be administered immediately following the clinic visit.

Time frame
Up to 3 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

UNC Lineberger Comprehensive Cancer Center

Lead sponsor

National Center for Advancing Translational Sciences (NCATS)

Collaborator

This trial is not recruiting at the moment. You can still explore other options: